On October 28, 2024, Research Team from ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco"), HKEX stock code: 01541.HK), announced that preclinical study data of IMM2520 were published in the journal Heliyon under the title "IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapy".

On February 16, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that the research team of ImmuneOnco completed the preclinical study of IMM2902. The results were published in "Drug Resistance Updates" under the title "Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy".

On September 26, 2023,the R&D team of ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) reported the preclinical research results of IMM40H under the tittle of ‘The Novel High-Affinity Humanized Antibody IMM40H Targets CD70, Eliminates Tumors Via Fc-mediated Effector Functions, and Interrupts CD70/CD27 Signaling’in the top journal Frontiers in Oncology’

Recently, the R&D team of ImmuneOnco reports the preclinical research results of IMM47 under the tittle of IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy " in the journal "Antibody Therapeutics".

On March 21, 2023, ImmuneOnco announced that the company will present the preclinical research data of IMM47 (CD24 antibody), IMM40H (CD70 antibody), IMM2520 (CD47×PD-L1), and IMM2902 (CD47×Her2) in the form of posters at the AACR 2023 Annual Meeting .